Drug-drug Interaction of Phenytoin Sodium and Methylprednisolone on Voriconazole: a Population Pharmacokinetic Model in Children with Thalassemia Undergoing Allogeneic Hematopoietic Stem Cell Transplantation

Overview

Journal Eur J Clin Pharmacol

Specialty Pharmacology

Date 2024 Dec 23

PMID 39714727

Authors

Yun Wu

Lu-Lu Niu

Ya-Yun Ling

Si-Ru Zhou

Tian-Min Huang

Jian-Ying Qi

Dong-Ni Wu

Rong-da Cai

Ting-Qing Wu

Yang Xiao

Taotao Liu

Affiliations

Soon will be listed here.

Abstract

Purpose: Voriconazole (VRC) is recommended for the prevention and treatment of invasive fungal infections in children undergoing hematopoietic stem cell transplantation (HSCT). It demonstrates nonlinear pharmacokinetics (PK) and exhibits substantial inter- and intraindividual variability. Phenytoin sodium (PHT) and methylprednisolone (MP) are commonly used in the early stages of HSCT to prevent epilepsy and graft-versus-host disease. Drug-drug interactions between VRC and these medications represent a significant concern in HSCT recipients. This study aims to investigate the effects of coadministration with PHT, MP, and other covariates on VRC metabolism in children with thalassemia (TM) undergoing allogeneic HSCT (Allo-HSCT) using population pharmacokinetics (PPK) and to recommend the optimal dosage regimen for this unique group.

Methods: A total of 237 samples from 57 children with TM undergoing Allo-HSCT were collected. Non-linear mixed effects modeling and Monte Carlo simulation (MCS) were applied for PPK analysis and for optimizing VRC dosing, respectively.

Results: The VRC data were characterized by a two-compartment model with linear elimination and first-order absorption. All parameters were incorporated in allometric scaling form, with PHT and MP significantly influencing VRC clearance. The MCS revealed a negative correlation between the children's body weight (ranging from 10 to 40 kg) and the required dose. When PHT was co-administered, approximately three times the regular dose of VRC was required. In contrast, when MP was administered together, the dose needed to be increased by 12.5-50%.

Conclusion: The proposed regimen improved the probability of target attainment for VRC and may serve as a reference for the individualized administration of VRC in clinical practice.

References

Bjorklund A, Aschan J, Labopin M, Remberger M, Ringden O, Winiarski J . Risk factors for fatal infectious complications developing late after allogeneic stem cell transplantation. Bone Marrow Transplant. 2007; 40(11):1055-62. DOI: 10.1038/sj.bmt.1705856. View

Omer A, Ziakas P, Anagnostou T, Coughlin E, Kourkoumpetis T, McAfee S . Risk factors for invasive fungal disease after allogeneic hematopoietic stem cell transplantation: a single center experience. Biol Blood Marrow Transplant. 2013; 19(8):1190-6. DOI: 10.1016/j.bbmt.2013.05.018. View

Shi J, Pei X, Luo Y, Tan Y, Tie R, He J . Invasive fungal infection in allogeneic hematopoietic stem cell transplant recipients: single center experiences of 12 years. J Zhejiang Univ Sci B. 2015; 16(9):796-804. PMC: 4569688. DOI: 10.1631/jzus.B1500005. View

Schulz J, Kluwe F, Mikus G, Michelet R, Kloft C . Novel insights into the complex pharmacokinetics of voriconazole: a review of its metabolism. Drug Metab Rev. 2019; 51(3):247-265. DOI: 10.1080/03602532.2019.1632888. View

Gautier-Veyret E, Thiebaut-Bertrand A, Roustit M, Bolcato L, Depeisses J, Schacherer M . Optimization of voriconazole therapy for treatment of invasive aspergillosis: Pharmacogenomics and inflammatory status need to be evaluated. Br J Clin Pharmacol. 2020; 87(6):2534-2541. DOI: 10.1111/bcp.14661. View

Theuretzbacher U, Ihle F, Derendorf H . Pharmacokinetic/pharmacodynamic profile of voriconazole. Clin Pharmacokinet. 2006; 45(7):649-63. DOI: 10.2165/00003088-200645070-00002. View

Zhao Y, Zou Y, Hou J, Xiao C, Zhang B, Li J . Factors Affecting Voriconazole Trough Concentration and Optimal Maintenance Voriconazole Dose in Chinese Children. Antibiotics (Basel). 2021; 10(12). PMC: 8698693. DOI: 10.3390/antibiotics10121542. View

Khan-Asa B, Punyawudho B, Singkham N, Chaivichacharn P, Karoopongse E, Montakantikul P . Impact of Albumin and Omeprazole on Steady-State Population Pharmacokinetics of Voriconazole and Development of a Voriconazole Dosing Optimization Model in Thai Patients with Hematologic Diseases. Antibiotics (Basel). 2020; 9(9). PMC: 7557832. DOI: 10.3390/antibiotics9090574. View

10.

van den Born D, Martson A, Veringa A, Punt N, van der Werf T, Alffenaar J . Voriconazole exposure is influenced by inflammation: A population pharmacokinetic model. Int J Antimicrob Agents. 2023; 61(4):106750. DOI: 10.1016/j.ijantimicag.2023.106750. View

11.

Tian X, Zhang C, Qin Z, Wang D, Yang J, Zhang X . Impact of CYP2C19 Phenotype and Drug-Drug Interactions on Voriconazole Concentration in Pediatric Patients. Antimicrob Agents Chemother. 2021; 65(9):e0020721. PMC: 8370228. DOI: 10.1128/AAC.00207-21. View

12.

Ashbee H, Barnes R, Johnson E, Richardson M, Gorton R, Hope W . Therapeutic drug monitoring (TDM) of antifungal agents: guidelines from the British Society for Medical Mycology. J Antimicrob Chemother. 2014; 69(5):1162-76. PMC: 3977608. DOI: 10.1093/jac/dkt508. View

13.

Chen K, Zhang X, Ke X, Du G, Yang K, Zhai S . Individualized Medication of Voriconazole: A Practice Guideline of the Division of Therapeutic Drug Monitoring, Chinese Pharmacological Society. Ther Drug Monit. 2018; 40(6):663-674. PMC: 6250289. DOI: 10.1097/FTD.0000000000000561. View

14.

Tang D, Yan M, Song B, Zhao Y, Xiao Y, Wang F . Population pharmacokinetics, safety and dosing optimization of voriconazole in patients with liver dysfunction: A prospective observational study. Br J Clin Pharmacol. 2020; 87(4):1890-1902. DOI: 10.1111/bcp.14578. View

15.

Pierrat A, Gravier E, Saunders C, Caira M, Ait-Djafer Z, Legras B . Predicting GFR in children and adults: a comparison of the Cockcroft-Gault, Schwartz, and modification of diet in renal disease formulas. Kidney Int. 2003; 64(4):1425-36. DOI: 10.1046/j.1523-1755.2003.00208.x. View

16.

El Edelbi R, Lindemalm S, Eksborg S . Estimation of body surface area in various childhood ages--validation of the Mosteller formula. Acta Paediatr. 2012; 101(5):540-4. DOI: 10.1111/j.1651-2227.2011.02580.x. View

17.

Gastine S, Lehrnbecher T, Muller C, Farowski F, Bader P, Ullmann-Moskovits J . Pharmacokinetic Modeling of Voriconazole To Develop an Alternative Dosing Regimen in Children. Antimicrob Agents Chemother. 2017; 62(1). PMC: 5740334. DOI: 10.1128/AAC.01194-17. View

18.

Moriyama B, Obeng A, Barbarino J, Penzak S, Henning S, Scott S . Clinical Pharmacogenetics Implementation Consortium (CPIC) Guidelines for CYP2C19 and Voriconazole Therapy. Clin Pharmacol Ther. 2016; 102(1):45-51. PMC: 5474211. DOI: 10.1002/cpt.583. View

19.

Takahashi T, Mohamud M, Smith A, Jacobson P, Jaber M, Alharbi A . CYP2C19 Phenotype and Body Weight-Guided Voriconazole Initial Dose in Infants and Children after Hematopoietic Cell Transplantation. Antimicrob Agents Chemother. 2021; 65(9):e0062321. PMC: 8370213. DOI: 10.1128/AAC.00623-21. View

20.

Friberg L, Ravva P, Karlsson M, Liu P . Integrated population pharmacokinetic analysis of voriconazole in children, adolescents, and adults. Antimicrob Agents Chemother. 2012; 56(6):3032-42. PMC: 3370730. DOI: 10.1128/AAC.05761-11. View

21.

Xu X, Yuan M, Karlsson M, Dunne A, Nandy P, Vermeulen A . Shrinkage in nonlinear mixed-effects population models: quantification, influencing factors, and impact. AAPS J. 2012; 14(4):927-36. PMC: 3475840. DOI: 10.1208/s12248-012-9407-9. View